Subjective Outcome
17 compoundsin Regimen’s catalog are configured to track sleep quality via Rate Today. Each one shows the dose range, listed benefits, and every outcome it’s set up to monitor. Tap through to plan a dose with the free reconstitution calculator.
Growth hormone is released in large pulses during the first few hours of sleep, and slow-wave (deep) sleep is the dominant phase during which the pituitary secretes it. GH secretagogues — CJC-1295, ipamorelin, MK-677, and tesamorelin — amplify this pulse pattern, and many users report a subjective improvement in sleep quality within the first 1–2 weeks.
The clinical evidence is mixed. MK-677 has the strongest dataset: in healthy older adults, 25 mg nightly for 2 years increased IGF-1 and was associated with improved subjective sleep, though objective polysomnography results were modest. CJC-1295 and ipamorelin have less rigorous human data but operate on the same axis.
Sleep quality is a Rate Today dimension in Regimen — a daily subjective score. Pairing it with the objective sleep metrics (total, REM, deep) from Apple Watch gives a complete picture without relying on either alone.
Anchor citation: Nass R et al.. Two-Year Treatment with the Oral Growth Hormone Secretagogue MK-677. Annals of Internal Medicine, 2008.
17 compounds
GHRH / GHRP Combination
A synergistic growth hormone releasing combination for body composition, sleep, and recovery.
Tracks
Tracks
Tracks
GHRH (1-29) Analog
Synthetic analog of the first 29 amino acids of growth hormone–releasing hormone. Stimulates the pituitary to release endogenous GH in pulses, preserving the natural feedback loop and avoiding suppressed pituitary axis seen with exogenous HGH.
Tracks
GHRH Analog (Egrifta)
Synthetic GHRH analog (modified GHRH 1-44) FDA-approved as Egrifta for HIV-associated lipodystrophy. Selectively reduces visceral adipose tissue and modestly elevates IGF-1 with a favorable safety profile relative to exogenous HGH.
Tracks
Tracks
Tracks
Tracks
Recombinant Human Growth Hormone
Recombinant DNA-derived 191-amino-acid growth hormone identical to endogenous human somatropin. FDA-approved for clinical GH deficiency (adult and pediatric); used off-label for body composition, recovery, and anti-aging. Direct hormone replacement — bypasses the pituitary axis (unlike Sermorelin/Tesamorelin).
Tracks
Lonapegsomatropin (TransCon hGH)
Skytrofa is a once-weekly, long-acting growth hormone for children with growth hormone deficiency (GHD). Lonapegsomatropin is a prodrug that slowly releases somatropin (hGH) over 7 days, providing stable GH levels with a single weekly injection instead of daily shots.
Tracks
Tracks
Tracks
Tracks
Tracks
Oral Ghrelin Mimetic / GH Secretagogue
An orally bioavailable, non-peptide ghrelin receptor agonist that produces sustained increases in GH and IGF-1 with once-daily dosing. Taken as a capsule — no reconstitution needed. Studied for sarcopenia, GH deficiency, and recovery support.
Tracks
Next-gen Ghrelin Receptor Agonist (research)
A research-grade non-peptide ghrelin receptor (GHS-R1a) agonist developed as a successor to MK-677. Vendor and analog modeling describe higher receptor affinity and longer half-life, but human clinical data are not yet published.
Tracks
Khavinson Pineal-Derived Tripeptide
A synthetic tripeptide (Glu-Asp-Arg) from Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation. Animal studies report reduced ROS in cerebellar granule and PC12 cells, plus improved cognitive outcomes in prenatal hyperhomocysteinemia and Alzheimer's mouse models.
Tracks
For users with a measured GH or IGF-1 deficit, CJC-1295/ipamorelin and MK-677 have the most coherent mechanism and the strongest anecdotal track record. DSIP (delta sleep-inducing peptide) is marketed specifically for sleep but has very limited modern clinical evidence. Outside the GH-secretagogue class, the highest-yield sleep intervention is typically not a peptide — it’s consistent sleep timing, cool dark room, and screen reduction.
Most users report a subjective deepening of sleep within the first 5–10 nights. The objective sleep-stage changes (REM, deep sleep duration) are more variable and may take 2–4 weeks to become consistent in Apple Watch data. The most reliable pattern is a reduction in night wakings and a sense of waking unprompted before the alarm.
Regimen reads sleep total, REM, deep, light, and time awake from Apple Health, which gets the data from Apple Watch or any compatible sleep tracker. Each metric shows next to the protocol’s dose log on the Tracked Outcomes view. The 30-day sparkline makes it easy to see whether your sleep architecture is improving as you titrate the dose.
Related reading
Best peptide tracker app in 2026
An honest multi-protocol comparison of Regimen, PeptIQ, Shotsy, MeAgain, and the GLP-1 calculator apps.
Other outcomes